Dr. Weber on CheckMate-238 for Melanoma

Jeffrey S. Weber, MD, PhD
Published: Monday, Sep 11, 2017



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.

CheckMate-238 is a large, randomized, phase III trial investigating nivolumab (Opdivo) versus ipilimumab (Yervoy) in patients with resected stage IIIb, IIIc, and IV melanoma, all of whom were at high risk of relapse, explains Weber.

There was a statistically significant and clinically impressive difference in relapse-free survival in favor of nivolumab compared with ipilimumab at an interim analysis, states Weber. Additionally, there was less toxicity reported in patients receiving nivolumab.
 


Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.

CheckMate-238 is a large, randomized, phase III trial investigating nivolumab (Opdivo) versus ipilimumab (Yervoy) in patients with resected stage IIIb, IIIc, and IV melanoma, all of whom were at high risk of relapse, explains Weber.

There was a statistically significant and clinically impressive difference in relapse-free survival in favor of nivolumab compared with ipilimumab at an interim analysis, states Weber. Additionally, there was less toxicity reported in patients receiving nivolumab.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x